[HTML][HTML] Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
Y Dargaud, C Escuriola‐Ettingshausen - Research and Practice in …, 2021 - Elsevier
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
[HTML][HTML] Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
Y Dargaud, C Escuriola‐Ettingshausen - Research and Practice in …, 2021 - rpthjournal.org
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
Y Dargaud… - Research and Practice in …, 2021 - Wiley Online Library
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021.
Y Dargaud… - Research and Practice in …, 2021 - europepmc.org
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
Y Dargaud… - Research and Practice in …, 2021 - search.proquest.com
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
[HTML][HTML] Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
Y Dargaud… - Research and Practice in …, 2021 - ncbi.nlm.nih.gov
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
Y Dargaud… - Research and practice …, 2021 - pubmed.ncbi.nlm.nih.gov
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of
anti-FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …
anti-FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …